Back to Explorer

Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry

FinalCenter for Biologics Evaluation and Research10/17/2023

Description

This guidance addresses certain requirements that apply to blood establishments that collect blood and blood components, including Source Plasma.  Specifically, the guidance explains the conditions under which FDA does not intend to take regulatory action for a blood establishment’s failure to comply with certain requirements in Title 21 of the Code of Federal Regulations 630.30 (21 CFR 630.30) regarding donation suitability; 21 CFR 630.10(c)(2) regarding donor eligibility; and 21 CFR 640.69(f) regarding quarantine hold for Source Plasma.

Scope & Applicability

Product Classes

4
Red Blood Cells

collected by apheresis

Whole Blood

Blood component subject to the recommendations in this guidance

Blood and Blood Component

scope of the compliance policy

Source Plasma

Specific blood component with distinct testing recommendations; Recommendations for testing Source Plasma differ from whole blood.

Stakeholders

5
registered-only establishment

establishments recommended to submit annual reports to OBRR

licensed establishment

establishments required to submit annual reports under 601.12

blood establishment

Entity responsible for implementing testing and deferral procedures

paid donors

donors of Source Plasma subject to quarantine hold requirements

blood establishments

Entities that collect blood and blood components; Entities responsible for testing donations and complying with regulations.

Regulatory Context

Attributes

1
quarantine hold

time period for holding Source Plasma before release; minimum timeframe before release for further manufacturing

Related CFR Sections (7)

See Also (8)

Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry | Guideline Explorer | BioRegHub